Product Name:

NebuPeptide™ Lutetium (177Lu) vipivotide tetraxetan (Peptide Reference)

Catalog Number:

NBS-233767

Description:

NebuPeptide™ Lutetium (177Lu) vipivotide tetraxetan (Peptide Reference)(CAT#NBS-233767) is synthesized in accordance with the Lutetium (177Lu) vipivotide tetraxetan sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Romiplostim reference peptide ranging from milligrams to kilograms.

Peptide Name:

Lutetium (177Lu) vipivotide tetraxetan

Background:

Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Lutetium (177Lu) vipivotide tetraxetan is a targeted radioligand therapy. Lutetium (177Lu) vipivotide tetraxetan is a radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium-177, with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium (177Lu) vipivotide tetraxetan, it targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.

Alias:

PSMA-617; WHO 11010; PSMA617; WHO-11010; PSMA 617; WHO11010;

CAS Number:

1702967-37-0

Formula:

C49H71N9O16

Molecular Weight:

1042.13 (Vipivotide tetraxetan (PSMA-617))

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.